

**ALKEM LABORATORIES LTD.**

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: [contact@alkem.com](mailto:contact@alkem.com) • Website: [www.alkemlabs.com](http://www.alkemlabs.com)
- CIN: L00305MH1973PLC174201

31<sup>st</sup> December, 2019

<b>The Corporate Relationship Department BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	---

Dear Sirs,

**Sub: Disclosure under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI Listing Regulations”).**

This is to intimate you that Alkem Laboratories Limited (the “Company”) has entered into an asset purchase agreement dated 30<sup>th</sup> December, 2019 with AbbVie Inc., USA (“Agreement”) for acquisition of certain assets as stated in Annexure I of this intimation letter related to the active pharmaceutical ingredient, Dronabinol (“Assets”). In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure I. A copy of these disclosures will be made available on the Company’s website as well in accordance with Regulation 30(8) of the SEBI Listing Regulations.

Kindly take note of the same.

Sincerely,  
For Alkem Laboratories Limited

  
**Manish Narang**  
President – Legal, Company Secretary & Compliance Officer

Encl: a/a



**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

**Annexure I**

Particulars	Remarks
Name of the entity from whom asset is acquired	AbbVie Inc, USA
Details of assets acquired	Assets as specified in the Agreement in relation to the active pharmaceutical ingredient, Dronabinol which include domain names and trademarks related to "MARINOL", New Drug Application registration with USFDA for Marinol, logos, patents, designs, know how, technical and manufacturing instructions, inventory, manufacturing equipment and such items.
Whether the acquisition falls under related party transaction and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length".	The acquisition does not fall under related party transaction.
Objects of acquisition	The Company shall own the NDA and associated assets and will use these to commercially exploit both Branded and Generic sales in US.
Brief details of any governmental or regulatory approvals required for the acquisition	None.
Nature of consideration- whether cash consideration or share swap and details of the same	Cash consideration.
Cost of acquisition	USD 10 million plus suitable Working Capital adjustments on closing.
The expected date of completion of acquisition	Simultaneous signing and closing as envisaged in the executed agreement i.e. on or before 31 <sup>st</sup> December, 2019.